Apellis Pharmaceuticals is a biotechnology company that owns the first-ever treatment for a common cause of blindness called geographic atrophy. It generated $1.00 billion in total revenue last year, a significant jump from $400 million just two years ago, driven by the rollout of its flagship drug, Syfovre. Despite this growth, the company recently reported that sales of its main eye drug actually fell 4% in 2025 as a major competitor entered the market.
The investment thesis on Apellis is that its 60% share of the eye-injection market is durable enough to fund its expansion into rare kidney diseases, which are less crowded and more profitable. While safety concerns and new competition from Astellas have slowed Syfovre's momentum, the underlying demand for any treatment that prevents blindness remains immense. If Apellis can maintain its lead in the eye market while its kidney drug, Empaveli, becomes a standard of care, the business becomes a diversified cash machine.
We view Apellis as a fairly valued leader in a high-stakes market where the easy growth has already been captured. The stock price currently reflects its lead, meaning future gains depend entirely on the kidney drug outperforming expectations. Any further safety issues with the eye drug would likely break the thesis immediately.
Apellis Pharmaceuticals stock dropped for years after it went public, but it has soared lately as the company found success selling a new eye drug. While the company is finally making a lot of money, investors are now worried that a new competitor will steal its customers and are questioning if the company is being sold for the right price.
What does it do?
Apellis Pharmaceuticals is a growth-stage biotechnology company that earns money by selling specialized drugs that regulate the "complement system," a part of the immune system that can cause damage when overactive. Money flows primarily from health insurers and government programs like Medicare, which pay for injections administered by doctors in clinics. The company’s lead product, Syfovre, is a direct injection into the eye used to slow the progression of geographic atrophy, an irreversible form of vision loss. Because there are no cures for these conditions, patients typically require ongoing, long-term treatment, creating a recurring revenue stream similar to a subscription model.
Where does revenue come from?
The vast majority of revenue comes from selling Syfovre to treat eye disease in the United States. For the full year 2025, Apellis reported preliminary U.S. product revenues of $689 million, with Syfovre accounting for $587 million and Empaveli bringing in $102 million. The company also earns significant income from a partnership with Sobi, which pays Apellis to sell its drugs in international markets like Europe.
Revenue Breakdown
Who are its customers?
Apellis Pharmaceuticals serves two primary groups: ophthalmologists treating eye disease and nephrologists treating rare kidney and blood disorders. The eye business is the larger driver, where the company delivered approximately 102,000 doses of Syfovre in the final quarter of 2025 alone. On the rare disease side, the company has received 267 new patient start forms for its kidney treatment since launching that specific use five months ago. These patients represent a 5% penetration of the estimated 5,000 people in the U.S. suffering from specific rare kidney conditions known as C3G and IC-MPGN.
What gives it staying power?
Apellis has a first-mover advantage and five years of clinical data that its competitors cannot easily replicate. Doctors are generally hesitant to switch stable patients to a newer drug unless it is significantly better. This "clinical inertia" helps Apellis maintain a 60% share of the eye-injection market despite new arrivals.
Where is it headed?
The company is making a major strategic bet on becoming a dominant player in rare kidney diseases. Management is currently running trials for two additional kidney conditions, FSGS and DGF, aiming to turn Empaveli into a "blockbuster" drug with over $1 billion in annual sales. If successful, this would reduce the company's reliance on the increasingly competitive eye market and provide a second path to long-term profitability.
The single most important trend is that Apellis has reached $1 billion in annual revenue but is seeing its core product growth stall. While total revenue grew year-over-year, sales of its flagship eye drug fell 4% in 2025, signaling that the company is no longer a "one-way" growth story.
Cash quality is improving as the company nears the point where it can pay its own way. Free cash flow was negative $90 million in 2024 but turned positive in 2025, which proves the company can finally generate cash from its operations instead of relying on investors.
The balance sheet is in a strong position with $466 million in cash available to fund the next several years of growth. With debt at a manageable 1.15x equity, Apellis has enough cushion to reach profitability without needing to sell more stock or take on risky loans.
Apellis is a business in transition that has finally proven its financial model works. While the slowdown in its main drug is a concern, the shift to positive cash flow means the company's survival is no longer in question.
The rare disease business is growing faster than expected, with Empaveli hitting 5% market penetration in just five months. This success in kidney disease provides a critical safety net that can offset the slowing growth in the eye-injection market.
Competition from Astellas’s rival drug, Izervay, is the single biggest threat to the current stock price. If Izervay continues to gain share, Syfovre revenue could continue to shrink, forcing the company to rely entirely on its smaller kidney disease drugs to survive.
The market for geographic atrophy treatments is roughly $1.5 billion today and is expected to reach $4 billion by 2030 as more patients are diagnosed. Pricing power in this industry is structural because these are the only treatments that exist for a disease that leads to permanent blindness. Apellis is currently the market leader, but it is a "challenger" to the traditional standard of care, meaning it must continuously prove its injections are worth the cost and risk to doctors.
This market is transitioning from a monopoly to a duopoly, which usually leads to higher marketing costs and pressure to offer better terms to insurers. Barriers to entry are high because of the decade-long clinical trials required, but once a rival enters, the battle for doctor loyalty is intense.
Astellas is the most dangerous threat because its drug, Izervay, has a cleaner safety profile and is growing its sales faster than Syfovre. Roche and Novartis are also looming threats in the kidney space, where they could bundle multiple drugs together to squeeze Apellis out of the clinic. Astellas has already captured 40% of the eye market, making it a peer-level threat in record time.
Apellis is under significant pressure and is currently losing market share to Astellas. Evidence for this is the 4% decline in Syfovre sales in 2025 while the overall market for these injections actually grew.
The primary source of protection is Apellis’s patent-protected technology and its five-year clinical data. Doctors are hesitant to switch patients to new drugs because of the high stakes of vision loss, which creates a meaningful but limited switching cost. The 90% gross margin is the clearest proof that Apellis can charge a premium for its specialized medicine.
However, these margins and the current 18% ROIC reflect the "winner-takes-most" period that is now ending. The numbers suggest Apellis has a good business but not a dominant one, as a single safety scare or a slightly better rival drug can quickly erode its position.
The moat is narrow and currently under pressure. The most important signal is whether the upcoming prefilled syringe can stop the flow of doctors moving to the competition.
Syfovre sales fell 4% in 2025 despite an expanding market.
Maintained $466M cash while moving toward self-funded profitability.
Co-Founder CEO has led the company from discovery to $1B revenue.
Capital Allocation Track Record
Management has proven they can take a drug from a lab to a billion-dollar market, but they have struggled to defend that market once competition arrived. While CEO Cedric Francois deserves credit for building a massive business from scratch, the recent decline in eye drug sales suggests the team was slow to react to rival Astellas. They have shown strong strategic judgment in pivoting to kidney disease, which has saved the company from being a one-hit wonder, but their execution in the eye market has been inconsistent.
The company remains heavily dependent on the vision and leadership of its co-founders, creating a key-person risk if Cedric Francois were to leave. There is a credible scientific bench, but the strategic direction of the company is tightly controlled by the founding team. While there are no major governance red flags, the concentrated control means investors are essentially trusting this specific team to win a two-front war against much larger pharmaceutical giants.
We expect revenue to grow from $0.9B in FY2026 to $1.4B in FY2031 (~11% CAGR), with EPS growing from $-1.03 to $3.00. SYFOVRE is gaining traction in the geographic atrophy market as the first-to-market treatment, driving steady adoption among ophthalmologists. Fixed manufacturing and corporate overhead costs are being spread across a larger revenue base as the product launch scales. EPS is growing faster than revenue because the company is Operating margin expected to reach ~30% by FY2031.
Empaveli becomes the standard of care for rare kidney diseases. If the kidney drug hits its targets, it adds a massive, high-margin revenue line that competitors cannot easily touch.
New prefilled syringe recaptures eye doctors frustrated by current injection tools. A more convenient injection method would stop doctors from switching to Astellas and stabilize the core business.
Positive data from next-generation treatment study (APL-3007) in 2027. Developing a better follow-up drug would protect the company's eye market lead for another decade.
Market share in eye care continues to slide toward 40% or lower. If Syfovre becomes the secondary choice for doctors, the company loses the cash flow needed to fund its other projects.
A major safety event leads to a drug recall or strict warning label. Any new reports of eye inflammation would permanently destroy trust in the brand and send sales to zero.
Large pharma rivals launch "good enough" drugs at significantly lower prices. Competitive pricing from giants like Novartis could crush margins in the rare kidney disease market.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We use a Forward P/E approach based on 2-year forward (FY2028) earnings estimates. This framework fits Apellis because the company recently achieved GAAP profitability ($0.15 EPS in Q1 2026), making earnings a cleaner signal of value than the revenue-based multiples typically used for loss-making biotech startups.
FY2028 EPS of $1.26 multiplied by a 32x multiple gives a per-share fair value of $41. A 32x multiple sits at the higher end of the profitable mid-cap biotech range (peers like SRPT and RARE trade between 22x and 35x), which is justified by the "buyout premium" from Biogen and the company's 90% gross margins. We use the $1.26 EPS figure provided in the deterministic projection to ensure consistency with the broader report's financial model.
Cross-checked with the deterministic engine’s 5-year Discounted Cash Flow (DCF), we arrive at a fair value of $40 — within 3% of our Forward P/E answer, confirming the result. The DCF accounts for the long-term cash flow profile of SYFOVRE and the ramp of the new kidney business, and its close alignment with our P/E math suggests the current market price of $41.03 is a rational reflection of the company's fundamental value under new ownership.
We're assuming Apellis maintains its 60% market share in the Geographic Atrophy (GA) market. GA is a leading cause of blindness, and while new competitors are entering, SYFOVRE's first-mover advantage and established physician relationships support a dominant position through FY2028.
We're assuming the EMPAVELI launch in C3G and IC-MPGN reaches 20% penetration by FY2028. These are rare kidney diseases with roughly 5,000 patients in the U.S.; this expansion leverages the company's existing expertise in "C3 biology" and provides a high-margin growth engine that offsets slowing growth in the eye-care segment.
The single biggest risk is the Biogen acquisition failing to close or being restructured at a lower price due to regulatory intervention. This would likely cause the multiple to contract from 32x toward a standalone biotech average of 18x, knocking roughly $15 off the per-share fair value. Watch for any "Second Request" from regulators regarding antitrust concerns in the complement-inhibitor market.
Bear case ($33): The Biogen acquisition faces regulatory delays or a price renegotiation due to safety concerns; or SYFOVRE market share falls below 50% as new competitors take share in the geographic atrophy market.
Bull case ($52): The kidney disease market adoption is 50% faster than expected, triggering higher contingent payments from Biogen; or SYFOVRE receives expanded approval in Europe, unlocking a significant new revenue stream.
Clearthesis wrote this report from 36 sources, including SEC filings, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on June 23, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.
The market is leaning bullish because the dominant market position in eye injections provides the cash flow needed to fund expansion into rare kidney disease treatments. Apellis has rapidly scaled its flagship drug to one billion dollars in annual revenue. This market footprint allows the company to diversify its pipeline into less crowded drug markets with higher profit margins.
Skeptics think that rising competition and slowing growth of the flagship eye drug make the current strategy too risky. Sales of the main eye treatment recently dropped four percent as a new rival entered the market, raising doubts about whether the core business can reliably fund the company's future pivot.